Advanced Biomed Inc. Common Stock
ADVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.13 | 1.69 | -8.96 | -2.69 |
| FCF Yield | -0.21% | -0.39% | -4.35% | -1.14% |
| EV / EBITDA | -626.60 | -653.99 | -1,975.89 | -2,889.42 |
| Quality | ||||
| ROIC | -0.54% | -0.83% | -0.54% | -0.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.05 | 2.58 | 81.04 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 65.53% | 98.26% | -310.49% | -1,573.75% |
| Safety | ||||
| Net Debt / EBITDA | 229.64 | 79.35 | -0.78 | 29.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.39 |
| Cash Conversion Cycle | -1,181.85 | -27,284.49 | -150,631.05 | -18,384.04 |